A citation-based method for searching scientific literature

Jagriti Upadhyay, Stergios A Polyzos, Nikolaos Perakakis, Bindiya Thakkar, Stavroula A Paschou, Niki Katsiki, Patricia Underwood, Kyung-Hee Park, Jochen Seufert, Eun Seok Kang, Elliot Sternthal, Asterios Karagiannis, Christos S Mantzoros. Metabolism 2018
Times Cited: 69







List of co-cited articles
400 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
14

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
13

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
8

Pharmacotherapy of obesity: Available medications and drugs under investigation.
Eleni Pilitsi, Olivia M Farr, Stergios A Polyzos, Nikolaos Perakakis, Eric Nolen-Doerr, Aimilia-Eirini Papathanasiou, Christos S Mantzoros. Metabolism 2019
46
13

Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i): Their Role in Cardiometabolic Risk Management.
Niki Katsiki, Dimitri P Mikhailidis, Michael J Theodorakis. Curr Pharm Des 2017
27
18

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, Khalid Jamal Farooqui, Manish Kumar Singh, Jasjeet Singh Wasir, Beena Bansal, Parjeet Kaur, Ganesh Jevalikar, Harmendeep Kaur Gill,[...]. Diabetes Care 2018
159
7

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Diabetes Obes Metab 2017
65
7

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Patrick M O'Neil, Andreas L Birkenfeld, Barbara McGowan, Ofri Mosenzon, Sue D Pedersen, Sean Wharton, Charlotte Giwercman Carson, Cecilie Heerdegen Jepsen, Maria Kabisch, John P H Wilding. Lancet 2018
146
7

The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD).
Elena Buzzetti, Massimo Pinzani, Emmanuel A Tsochatzis. Metabolism 2016
723
7

Association of Adipokines with Development and Progression of Nonalcoholic Fatty Liver Disease.
Chrysoula Boutari, Nikolaos Perakakis, Christos Socrates Mantzoros. Endocrinol Metab (Seoul) 2018
53
9


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
5

Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes.
Gary E Meininger, Russell Scott, Maria Alba, Yue Shentu, Edmund Luo, Himal Amin, Michael J Davies, Keith D Kaufman, Barry J Goldstein. Diabetes Care 2011
119
5

Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Hristo Iliev, Egon Pfarr, Bernard Zinman. Diabetes Care 2018
84
5

Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: Effects of statins and antidiabetic drugs.
Niki Katsiki, Vasilios G Athyros, Dimitri P Mikhailidis. J Diabetes Complications 2017
23
17

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
5

Future Pharmacotherapy for Obesity: New Anti-obesity Drugs on the Horizon.
Gitanjali Srivastava, Caroline Apovian. Curr Obes Rep 2018
67
5

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Caroline M Apovian, Louis Aronne, Domenica Rubino, Christopher Still, Holly Wyatt, Colleen Burns, Dennis Kim, Eduardo Dunayevich. Obesity (Silver Spring) 2013
225
5

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Rohan Khera, Mohammad Hassan Murad, Apoorva K Chandar, Parambir S Dulai, Zhen Wang, Larry J Prokop, Rohit Loomba, Michael Camilleri, Siddharth Singh. JAMA 2016
236
5

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
608
5

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
5

The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Vasilios G Athyros, Theodore K Alexandrides, Helen Bilianou, Evangelos Cholongitas, Michael Doumas, Emmanuel S Ganotakis, John Goudevenos, Moses S Elisaf, Georgios Germanidis, Olga Giouleme,[...]. Metabolism 2017
114
5

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.
Zobair Younossi, Quentin M Anstee, Milena Marietti, Timothy Hardy, Linda Henry, Mohammed Eslam, Jacob George, Elisabetta Bugianesi. Nat Rev Gastroenterol Hepatol 2018
5


Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Matthew James Armstrong, Piers Gaunt, Guruprasad P Aithal, Darren Barton, Diana Hull, Richard Parker, Jonathan M Hazlehurst, Kathy Guo, George Abouda, Mark A Aldersley,[...]. Lancet 2016
622
5

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.
Boyu Li, Ying Wang, Zhikang Ye, Hui Yang, Xiangli Cui, Zhenjun Wang, Lihong Liu. J Pharm Pharm Sci 2018
16
25


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
880
5

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
Stergios A Polyzos, Jannis Kountouras, Christos S Mantzoros. Metabolism 2019
116
5

Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study.
Nikolaos Perakakis, Stergios A Polyzos, Alireza Yazdani, Aleix Sala-Vila, Jannis Kountouras, Athanasios D Anastasilakis, Christos S Mantzoros. Metabolism 2019
24
16

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Naga Chalasani, Zobair Younossi, Joel E Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A Harrison, Elizabeth M Brunt, Arun J Sanyal. Hepatology 2018
5

A review of the efficacy and safety of oral antidiabetic drugs.
Stephanie Aleskow Stein, Elizabeth Mary Lamos, Stephen N Davis. Expert Opin Drug Saf 2013
145
4

PPARγ signaling and metabolism: the good, the bad and the future.
Maryam Ahmadian, Jae Myoung Suh, Nasun Hah, Christopher Liddle, Annette R Atkins, Michael Downes, Ronald M Evans. Nat Med 2013
872
4

Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy.
Khurrum Shahzad, Fabian Bock, Wei Dong, Hongjie Wang, Stefan Kopf, Shrey Kohli, Moh'd Mohanad Al-Dabet, Satish Ranjan, Juliane Wolter, Christian Wacker,[...]. Kidney Int 2015
175
4

Inflammation and the pathogenesis of diabetic nephropathy.
Jun Wada, Hirofumi Makino. Clin Sci (Lond) 2013
326
4

Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes.
Hye-Mi Lee, Jwa-Jin Kim, Hyun Jin Kim, Minho Shong, Bon Jeong Ku, Eun-Kyeong Jo. Diabetes 2013
361
4

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis.
O J Phung, D M Sobieraj, S S Engel, S N Rajpathak. Diabetes Obes Metab 2014
70
4


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
4

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
4


Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study.
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao'e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang,[...]. Lancet Diabetes Endocrinol 2018
14
21

Decreased expression of hepatic glucokinase in type 2 diabetes.
Rebecca A Haeusler, Stefania Camastra, Brenno Astiarraga, Monica Nannipieri, Marco Anselmino, Ele Ferrannini. Mol Metab 2014
41
7

Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
Niki Katsiki, Francesco Purrello, Costas Tsioufis, Dimitri P Mikhailidis. Expert Opin Pharmacother 2017
27
11

Antidiabetic Drugs as Antihypertensives: New Data on the Horizon.
Vassiliki Mamakou, Ioanna Eleftheriadou, Niki Katsiki, Konstantinos Makrilakis, Konstantinos Tsioufis, Nikolaos Tentolouris. Curr Vasc Pharmacol 2017
3
100

Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy.
Juan F Navarro-González, Carmen Mora-Fernández, Mercedes Muros de Fuentes, Javier García-Pérez. Nat Rev Nephrol 2011
506
4

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.
Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, Eric Mayoux, Shuichi Kaneko, Tsuguhito Ota. EBioMedicine 2017
110
4

Mechanisms, Pathophysiology, and Management of Obesity.
Steven B Heymsfield, Thomas A Wadden. N Engl J Med 2017
480
4

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
391
4


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.